Company / Profit Margin
Arbutus Biopharma Corp Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-237.9%
FY2025
5-year range
-1133.0% / -178.0%
FY2021-FY2025
Trend
+79.0%
vs FY2024
Sector context
#113 of 146
Health Care
What the data says
Arbutus Biopharma Corp's profit margin of -237.9% is lower than 77% of companies in the Health Care sector (FY2025). Profit Margin returned to growth in FY2025 after 2 years of decline, reaching -237.9%.
Based on SEC 10-K filings.
-237.9% in FY2025 with a 5-year CAGR of +2319.5%.
Improved from -401.6% to -237.9% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- -59.9pp
- 5-Year Change
- +2319.5pp
- 10-Year Change
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 146This company -237.9% Sector average -796.3%
▼
+70.1% above sector average
Key checks
Key Insights
- In FY2025, profit margin increased 79.0% year-over-year.
- Currently 558.4pp above the Health Care sector average.
- Peak profit margin was recorded in FY2022.
- Lowest profit margin in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -237.9% | +79.0% |
| FY2024 | -1133.0% | -182.2% |
| FY2023 | -401.6% | -125.6% |
| FY2022 | -178.0% | +74.3% |
| FY2021 | -693.9% | +72.9% |
| FY2020 | -2557.4% | -65.8% |
| FY2019 | -1542.1% | -95.5% |
| FY2018 | -788.9% | +0.0% |
| FY2017 | -788.9% | +96.9% |
| FY2016 | -25765.5% | -9462.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026